Biocompatible superparamagnetic sub-micron vaterite particles for thermo-chemotherapy: From controlled design to in vitro anticancer synergism

Publication date: January 2020Source: Materials Science and Engineering: C, Volume 106Author(s): Ghizlane Choukrani, Bikendra Maharjan, Chan Hee Park, Cheol Sang Kim, Arathyram Ramachandra Kurup SasikalaAbstractA promising candidate for the development of controlled and targeted nanoscale drug delivery system but less studied so far is calcium carbonate (CaCO3) in the form of porous polycrystalline vaterite spheres. Vaterite has been shown to exhibit various beneficial properties such as excellent biocompatibility, high drug loading capacity, and pH-sensitive decomposition under mild conditions. However, fabricating vaterite particles with improved porosity, high surface area and loading a payload into the common synthesis method is still a challenge. Here we report on the synthesis of a highly porous, spherical superparamagnetic vaterite particles (PMVP) of size ∼800 nm encapsulating Iron oxide nanoparticles (IONPs) in a one-step reaction and loaded with DOX molecules through electrostatic attractions and physisorption for cancer thermo-chemotherapy application. The main advantage of the PMVP-DOX is that it can be magnetically targeted into the tumor region and once exposed to the tumor tissues characteristic acidic pH, the PMVP nanoparticle dissociates, releasing the DOX and intelligently converts the pH-triggered drug release into a tumor triggered drug release. Simultaneous application of alternating magnetic field (AMF) generates localized heat of the tumor tissues...
Source: Materials Science and Engineering: C - Category: Materials Science Source Type: research

Related Links:

Conclusion: Our results suggest a greater role of nongenetic factors in PTP inhibitor development. PMID: 31730688 [PubMed]
Source: Blood Research - Category: Hematology Tags: Blood Res Source Type: research
CONCLUSIONS: neoadjuvant chemotherapy is a promising alternative in the locally advanced rectal cancer setting and further phase III clinical trials are clearly warranted. PMID: 31729235 [PubMed - as supplied by publisher]
Source: Revista Espanola de Enfermedades Digestivas - Category: Gastroenterology Tags: Rev Esp Enferm Dig Source Type: research
This study aimed to review previous invitro and invivo investigations on anticancer effects of this carotenoid and also proposed molecular mechanisms of its action. Literature reviewing between 1990 and 2017 was performed using pubmed and scopus databases. Anti-proliferative and pro-apoptotic effects of crocetin have been observed in several cancers cell lines and also model organisms that might be due to the alternation in the expression of cancer-related genes and epigenetic changes. Moreover, several studies indicated synergistic effects of crocetin with common chemotherapy agents and mentioned it as a potential novel adjuvant therapy.
Source: Current Cancer Therapy Reviews - Category: Cancer & Oncology Source Type: research
Abstract BACKGROUND: Intraperitoneal (IP) chemotherapy is often a preferred treatment for ovarian cancer because of its clinical benefits, but research on the experiences of patients receiving IP chemotherapy is limited. OBJECTIVES: The purpose of this article is to explore the lived experiences of Taiwanese patients diagnosed with ovarian cancer who have received at least one cycle of IP chemotherapy. METHODS: A semistructured interview guide was used to collect data. Interviews were analyzed using a qualitative content analysis. FINDINGS: The following themes emerged from the data. PMID: 3173...
Source: Clinical Journal of Oncology Nursing - Category: Nursing Authors: Tags: Clin J Oncol Nurs Source Type: research
Abstract BACKGROUND: Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with programmed cell death protein 1 (PD-1) inhibitors has been associated with risk of developing immune-mediated adverse reactions (IMARs). OBJECTIVES: This review provides nurses with an overview of the safety of PD-1 inhibitors approved by the U.S. Food and Drug Administration for recurrent or metastatic SCCHN following platinum chemotherapy, as well as recommendations for assisting with the diagnosis and management of IMARs. METHODS: PubMed® searches were conducted to iden...
Source: Clinical Journal of Oncology Nursing - Category: Nursing Authors: Tags: Clin J Oncol Nurs Source Type: research
The objective of this paper is to synthesise current knowledge on ALK rearrangement and its impact on the management of advanced NSCLC. Several inhibitors of the tyrosine kinase of ALK (crizotinib, ceritinib, alectinib) have been approved as first line therapies in patients with advanced ALK positive NSCLC, which are associated with a better median progression-free survival than conventional chemotherapy. Unfortunately, the emergence of drug resistance leads to tumor progression. In patients with oligoprogressive disease if local ablative therapy can be effected, continuing with the same ALK tyrosine kinase inhibitor is on...
Source: Revue des Maladies Respiratoires - Category: Respiratory Medicine Tags: Rev Mal Respir Source Type: research
Publication date: Available online 15 November 2019Source: Biotechnology ReportsAuthor(s): Pradeep Kumar, Balwant Singh, Vikram Thakur, Abhishek Thakur, Nandita Thakur, Deepak Pandey, Duni ChandAbstractTaxol® (generic name Paclitaxel) is a chemotherapeutic drug, effective against head, neck, breast, lung, bladder, ovary, and cervix cancers. Rising demands in chemotherapy and limited supply of natural taxol have ultimately increased the cost of the drug. Semi synthesis using taxol precursors is not able to meet the global supply and has intensified the need to find alternative ways of taxol production. In the present st...
Source: Biotechnology Reports - Category: Biotechnology Source Type: research
Authors: Yang JD, Ma L, Zhu Z Abstract We assessed the expression of Serpin Family E Member 1 (SERPINE1) and its prognostic values in gastric adenocarcinoma (GAC) by using the data from TCGA database. The biological functions of SERPINE1 in GAC cells were detected by cell counting Kit-8, colony-forming, Transwell, and wound-healing assays, appropriately. Relative mRNA and protein levels were detected by RT-qPCR and western blot. Bioinformatics analysis indicated that SERPINE1 was significantly up-regulated in GAC tissues compared to normal tissues. High SERPINE1 expression led to a short overall survival and could ...
Source: Journal of Chemotherapy - Category: Cancer & Oncology Tags: J Chemother Source Type: research
Authors: Grothey A, Marshall JL, Bekaii-Saab T Abstract The standard treatment for patients with metastatic colorectal cancer (mCRC) in the first- and second-line setting is generally chemotherapy, which can be augmented with vascular endothelial growth factor-targeted therapies and, for patients with KRAS wild-type status, epidermal growth factor receptor-targeted therapies. However, nearly all patients ultimately develop disease progression and require later lines of therapy. Traditionally, physicians recycled chemotherapy in the later lines, with many patients showing diminished or no response. However, the past...
Source: Clinical Advances in Hematology and Oncology - Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research
AbstractThe recent genomic characterization of urothelial carcinoma by the Cancer Genome Atlas Project, made possible by the introduction of high throughput, reduced cost, and sequence analysis, has shed new insights on the biology of advanced disease. In addition, studies on imaging of advanced urothelial carcinoma have widened the knowledge on disease presentation and on pattern of metastatic spread and their correlation with the underlying biology of urothelial carcinoma. The wide range of treatments for advanced urothelial cancer, including combined chemotherapy regimens and immune checkpoint inhibitors, each result in...
Source: Abdominal Imaging - Category: Radiology Source Type: research
More News: Calcium | Cancer | Cancer & Oncology | Chemotherapy | Iron | Materials Science | Nanotechnology | Science